ANALISA BIOINFORMATIKA GEN E1 DAN E2 DARI VIRUS HEPATITIS C (HCV) GENOTIPE 1, 2, 3 DAN 6 SEBAGAI KANDIDAT VAKSIN VIRALLIKE PARTICLES (VLP)

Henny Saraswati

Abstract


Hepatitis C virus (HCV) causes hepatitis disease. This disease is dangerous due to the large number of people with chronic hepatitis infection. Chronic hepatitis infection may progress to cirrhosis, liver cancer and death. The mortality rate due to liver cancer is quite large and occupies the top 10 causes of death in the world. HCV vaccine is necessary to prevent HCV transmission. The challengeof this vaccine developmentis the genotypes circulate in the world. In Indonesia, there are genotypes 1, 2, 3 and 6. HCV vaccine should be able to protect from most genotype. Therefore, the development of HCV vaccine takes a long time. One vaccine approach sounds promisingis VLP (Viral-like Particles) vaccine. The E1 E2 protein on the surface of the virus is an excellent candidate for VLP vaccine material, because of its immunogenecity. In this study, we didbioinformatics studyto analyzes E1 and E2 genes from genotypes 1, 2, 3 and 6. These genes sequences are obtained fromGenBank, and analyzed further using softwares such as BioEdit Sequence Alignment Editor, BLAST and BLAST Primer. From this study we can obtain E1-E2 gene consensus sequence and also conserved region of E1 and E2 gene sequence. The results of this study can be further used in the development of HCV VLP vaccine candidates.

Full Text:

PDF

References


Ashfaq,U.A, T.Javed, S.Rehman, Z.Nawaz dan S.Riazuddin. (2011). An overview of HCV molecular biology, replication and immune responses. Virol J. 8:161.

Asselah, T, N. Boyer, D. Saadoun, M. MartinotPeignoux dan P. Marcellin. (2016). DirectActing Antivirals for The Treatment of Hepatitis C Virus Infection: Optimizing Current IFN-free Treatment and Future Perspective. Liver Int. 36 (Suppl. S1): 4757.

Bartosch, B, J. Dubuisson dan F.C Cosset. (2003). Infectious Hepatitis C Virus Pseudoparticles Containing Functional E1-E2 Envelope Protein Complexes. J. Exp. Med. 197(5): 633-642.

Bassett, S.E, D.L Thomas, K.M. Brasky, dan R.E Lanford. (1999). Viral Persistence, Antibody to E1 and E2, and Hypervariable Region 1 Sequence stability in Hepatitis C Virus

inoculated Chimpanzees. J. Virol. 73(2): 1118-1126.

Beaumont, E dan P. Roingeard. (2013). Prospect for Prophylactic Hepatitis C Vaccines Based on Virus Like Particles. Hum. Vaccin. Immunother. 9(5): 1112-1118.

Beaumont, E, E. Roch, L. Chopin, dan P. Roingeard. (2016). Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive Properties. PLoS ONE. 1-15.

Deng, K, R.Liu, H.Rao, D.Jiang, J.Wang, X.Xie, L.Wei. (2015). Antibodies Targetting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection. PloS ONE 10(9): 1-17.

Dubuisson, J. (2007). Hepatitis C virus proteins. World J Gastroenterol 2007 May 7; 13(17): 2406-2415.

Frey, S.E, M.Houghton, S.Coates, S.Abrignani, D.Chien, D.Rosa, P.Pileri, R.Ray, A.M.Di Bisceglie, P.Rinella, H.Hill, M.C. Wolff, V.Schultze, J.H. Han, B.Scharschmidt, R.B. Belshe. (2010). Safety and immunogenicity ofHCVE1E2vaccineadjuvantedwithMF59ad ministered to healthy adults. Vaccine 28 (2010) 6367–6373.

Garrone, P, A.C.Fluckiger, P.E. Mangeot, E. Gauthier, P.Dupeyrot-Lacas, J.Mancip, A. Cangialosi, I.Du Chéné, R. LeGrand, I.Mangeot, D.Lavillette, B.Bellier, F.L Cosset, F.Tangy, D.Klatzmann, C.Dalba. (2011). A Prime-Boost Strategy Using Virus-Like Particles Pseudotyped for HCV Proteins Triggers Broadly Neutralizing Antibodies in Macaques. Sci. Transl. Med., 3(94):94ra71.

Halliday, J., P.Klenerman dan E. Barnes. (2011). Vaccination for Hepatitis C Virus: Closing an Evasive Target. Expert Rev. Vaccine. 10(5): 659-672.

InfoDATIN. (2014). Situasi dan Analisis Hepatitis. Kementerian Kesehatan Republik Indonesia.

Kushnir, N, S.Streatfield, V.Yusibov. (2012). Viruslike particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. Vaccine. 31(1):58-83.

Li, C, V.H. Pham, K. Abe, L. Lu. (2014). Nine Additional Complete Genome Sequences of HCV Genotype 6 from Vietnam Including New Subtypes 6xb and 6xc. Virology. 468470: 172-177.

Li, L, C. Li, Y. Fu, F. Gao, O.G. Pybus, K. Abe, H. Okamoto, C.H. Hagedorn, D. Murphy. (2007). Complete Genomes of Hepatitis C Virus (HCV) Subtypes 6c, 6l, 6o, 6p and 6q: Completion of a Full Panel of Genomes for HCV Genotype 6. J. Gen. Virol. 88(5):15191525.

Lu, L, T. Wu, L. Xiong, C. Li, M.H. Nguyen, D.G. Murphy. (2016). Analysis of HCV-6 Isolates Among Asian-born Immigrants in NorthAmerica Reveals Their High Genetic Diversity and a New Subtype. Virology. 492: 25-31.

Lu, L, Y. Yu, D.G. Murphy. (2014). Full-length genomes of 16 hepatitis C virus genotype 1 isolates representing subtypes 1c,1d,1e, 1g, 1h, 1i, 1j and 1k, and two new subtypes 1mand1n,andfourunclassifiedvariantsreveal ancestral relationships among subtypes. J. Gen. Virol. 95 : 1479-1487.

Martínez-Donato,G, B.Piniella, D.Aguilar, S.Olivera, A.Pérez, Y.Castañedo, L.Alvarez-Lajonchere, S.Dueñas-Carrera, J.W.Lee, N.Burr, M.Gonzalez-Miro, B.H.A.Rehm. (2016). Protective T-Cell and Antibody Immune Responses against Hepatitis C Virus Achieved Using a Biopolyester-Bead-Based Vaccine Delivery System. Clin Vaccine Immunol 23:370–378.

Messina, J.P, I.Humphreys, A. Flaxman, A.Brown, G.S. Cooke, O.G. Pybus dan E. Barnes. (2015). Global Distribution and Prevalence of Hepatitis C Virus. Hepatology. 61: 77-87.


Refbacks

  • There are currently no refbacks.





Indonesian Journal of Biotechnology and Biodiversity

ISSN 2581-0014

published by:

Department of Biotechnology, Faculty of Health, Universitas Esa Unggul

Jalan Arjuna Utara No. 9, Kebon Jeruk, Jakarta Barat